BAM-15 Overview, Dosing & Safety | Peptide Database

BAM-15 (BAM15)

Mitochondrial Uncoupler | Metabolic Enhancer

Community Research

Join others researching BAM-15 — share findings, ask questions, and learn from real experiences

BAM-15 is a synthetic mitochondrial uncoupler that has emerged as a promising research compound for obesity and metabolic disorders. Unlike traditional uncouplers like DNP which have serious toxicity concerns, BAM-15 demonstrates a superior safety profile while effectively increasing energy expenditure and fat oxidation. Research in mice shows BAM-15 reduces body fat without affecting food intake, lean mass, or body temperature. It is approximately 7-fold more potent than DNP and does not induce the dangerous hyperthermia associated with older uncouplers. Note: BAM-15 is a small molecule compound, not a peptide, but is commonly sold alongside peptide products.

BAM-15 targets the inner mitochondrial membrane, enhancing proton permeability and dissipating the proton gradient. This uncouples electron transport from ATP synthesis, forcing mitochondria to increase respiration and burn more substrates (particularly fat) to maintain energy production. BAM-15 activates AMP-activated protein kinase (AMPK) in response to ATP depletion, promoting glucose uptake and fatty acid oxidation. It also activates PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha), enhancing mitochondrial biogenesis. Unlike DNP or FCCP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective concentrations, explaining its improved safety profile.

Molecular Data

Complex or non-standard sequence format

Research Indications

Reduces body fat by increasing energy expenditure and fat oxidation without reducing food intake.

Research shows reversal of diet-induced insulin resistance in mouse models.

Addresses multiple components of metabolic syndrome through enhanced energy expenditure.

2024 research shows combining BAM-15 with semaglutide produces stronger metabolic benefits than either alone by countering metabolic adaptation.

May help overcome weight loss plateaus by preventing metabolic adaptation/efficiency.

Research shows decreased liver triglycerides in treated animals.

Improved glucose tolerance observed in research models.

Dosing Protocols

BAM-15 is orally bioavailable and is typically administered as an oral supplement in tablet or capsule form. Research in mice used dietary supplementation (0.1% of diet) or oral gavage dosing. Human dosing protocols are still being established through ongoing research. The compound has a relatively short half-life, which researchers are working to improve through structural modifications.

Metabolic enhancement

25-50 mg

Once or twice daily

Oral

Research protocol (mouse equivalent)

~10 mg/kg

Daily

Oral gavage

Interactions

What to Expect

Side Effects & Safety

Common Side Effects

Generally well-tolerated in research

Possible mild increase in body temperature (less than DNP)

Stop Signs - Discontinue if:

Significant hyperthermia/overheating

Excessive sweating

Rapid heart rate

Difficulty breathing

Contraindications

Hyperthyroidism or thyroid disorders

Heart conditions

Pregnancy or breastfeeding

Use of other mitochondrial uncouplers (DNP, FCCP)

Fever or active infection

Quality Checklist

Good Signs

White to off-white powder or tablets

Certificate of analysis with purity >98%

Proper packaging protected from light

Reputable supplier

Warning Signs

No third-party testing available

Unclear sourcing

Bad Signs

Discolored product

No purity information

Unknown origin

Frequently Asked Questions

How does BAM-15 avoid the dangerous hyperthermia of DNP?

BAM-15 is approximately 7-fold more potent than DNP but does not induce the dangerous, uncontrollable hyperthermia DNP causes. BAM-15 enhances mitochondrial proton permeability selectively without depolarizing plasma membranes or triggering systemic heat production. It activates compensatory AMPK and PGC-1α pathways instead of creating metabolic chaos.

Can BAM-15 cause fat loss without diet and exercise?

Research in mice showed BAM-15 reduced body fat without affecting food intake or body temperature, but those were sedentary rodents. Human efficacy requires unclear interaction with actual behavior, diet, and exercise. Results are likely enhanced by caloric deficit and training, not achieved passively.

Why does 2024 research show BAM-15 works better with semaglutide?

Combining BAM-15 (mitochondrial uncoupler) with semaglutide (GLP-1 agonist) produces stronger metabolic benefits than either alone by countering metabolic adaptation. Semaglutide's appetite suppression plateaus as the body adapts; BAM-15's energy expenditure boost prevents this adaptation, allowing sustained weight loss.

Is BAM-15 safer than other mitochondrial uncouplers like FCCP?

Yes. Unlike FCCP and traditional uncouplers like DNP, BAM-15 does not depolarize plasma membranes or induce apoptosis at effective doses. This selective mitochondrial targeting makes it substantially safer, though human safety data remains limited. It's still a research chemical without FDA approval.

References

BAM15 is orally bioavailable, increases nutrient oxidation, decreases body fat mass without altering food intake, lean mass, body temperature, or markers of toxicity.

BAM15 is 7-fold more potent than DNP, does not depolarize plasma membranes, and does not induce apoptosis at effective doses.

Comprehensive review of BAM15 mechanisms including AMPK and PGC-1α activation pathways.

Combining semaglutide and BAM15 produces stronger metabolic benefits than either alone; helps overcome metabolic adaptation.

Related Peptides

Similar synergy expected as with semaglutide; helps overcome weight loss plateaus.

Both affect mitochondrial function but through different mechanisms.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.